Gregory R. Pond, PhD, on Urothelial Cancer: Advance in Prognosis

2018 Genitourinary Cancers Symposium
Tweet this page

Gregory R. Pond, PhD, of McMaster University, discusses a new six-factor prognostic model for patients with advanced urothelial carcinoma receiving post platinum atezolizumab (Abstract 413).

Advertisement

Advertisement

Advertisement